Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Refractory Large B-cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-06-28

Last Posted Date: 2024-02-20

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 27

Registration Number: NCT04002401

Locations: 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 11 locations

Descartes-11 in Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: Descartes-11
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-06-21

Last Posted Date: 2024-10-01

Lead Sponsor: Cartesian Therapeutics

Target Recruit Count: 25

Registration Number: NCT03994705

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
Medical College of Wisconsin, Madison, Wisconsin, United States

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor, Adult

Interventions: Other: TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2
Other: Radiotherapy

First Posted Date: 2019-06-20

Last Posted Date: 2021-03-18

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 6

Registration Number: NCT03992326

Locations: 🇨🇭
CHUV Oncology Department, Lausanne, Vaud, Switzerland

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Refractory B Lymphoblastic Lymphoma
Recurrent B Lymphoblastic Lymphoma
Refractory B Acute Lymphoblastic Leukemia

Interventions: Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Cyclophosphamide
Biological: Inotuzumab Ozogamicin

First Posted Date: 2019-06-19

Last Posted Date: 2023-07-06

Lead Sponsor: University of Washington

Target Recruit Count: 24

Registration Number: NCT03991884

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Phase 2

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Diffuse Large B-Cell Lymphoma
Double-Expressor Lymphoma
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Procedure: Lumbar Puncture
Procedure: Positron Emission Tomography
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate
Drug: Venetoclax

First Posted Date: 2019-06-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 363

Registration Number: NCT03984448

Locations: 🇺🇸
Saint Anthony Hospital, Lakewood, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States
🇺🇸
Littleton Adventist Hospital, Littleton, Colorado, United States

and more 633 locations

BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

Phase 2

Conditions: Idiopathic Multicentric Castleman's Disease

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethason

First Posted Date: 2019-06-12

Last Posted Date: 2019-06-12

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT03982771

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Optimizing PTCy Dose and Timing

Phase 1

Recruiting

Conditions: Hematologic Neoplasms
Graft Versus Host Disease

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2019-06-12

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 400

Registration Number: NCT03983850

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Acute Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Radiation: Total-Body Irradiation
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Peripheral Blood Stem Cell
Drug: Tacrolimus
Biological: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Drug: Methotrexate
Drug: Cyclosporine
Drug: Busulfan
Drug: Sirolimus
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Procedure: Biospecimen Collection

First Posted Date: 2019-05-31

Last Posted Date: 2024-08-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 120

Registration Number: NCT03970096

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Phase 2

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Letetresgene autoleucel (lete-cel, GSK3377794)
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-05-30

Last Posted Date: 2024-10-11

Lead Sponsor: Adaptimmune

Target Recruit Count: 103

Registration Number: NCT03967223

Locations: 🇪🇸
Hospital Virgen Del Rocio, Sevilla, Spain
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States

and more 34 locations

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Phase 3

Recruiting

Conditions: Testicular Leukemia
B Lymphoblastic Lymphoma
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Central Nervous System Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Calaspargase Pegol
Procedure: Bone Scan
Drug: Cyclophosphamide
Procedure: Computed Tomography
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Cytarabine
Drug: Doxorubicin Hydrochloride
Drug: Leucovorin Calcium
Biological: Inotuzumab Ozogamicin
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Procedure: Magnetic Resonance Imaging
Drug: Prednisolone
Other: Questionnaire Administration
Radiation: Radiation Therapy
Procedure: Positron Emission Tomography
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2019-05-22

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 4997

Registration Number: NCT03959085

Locations: 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

and more 225 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy